171 related articles for article (PubMed ID: 10514908)
1. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
2. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
3. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
4. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
5. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.
Valli A; Sette A; Kappos L; Oseroff C; Sidney J; Miescher G; Hochberger M; Albert ED; Adorini L
J Clin Invest; 1993 Feb; 91(2):616-28. PubMed ID: 7679413
[TBL] [Abstract][Full Text] [Related]
6. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
7. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
8. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules.
Adams S; Albericio F; Alsina J; Smith ER; Humphreys RE
Arzneimittelforschung; 1997 Sep; 47(9):1069-77. PubMed ID: 9342425
[TBL] [Abstract][Full Text] [Related]
9. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins.
Zavala-Ruiz Z; Strug I; Anderson MW; Gorski J; Stern LJ
Chem Biol; 2004 Oct; 11(10):1395-402. PubMed ID: 15489166
[TBL] [Abstract][Full Text] [Related]
10. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
[TBL] [Abstract][Full Text] [Related]
11. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
12. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
13. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
Yaneva R; Springer S; Zacharias M
Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
[TBL] [Abstract][Full Text] [Related]
14. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
15. MHC class II binding of peptides derived from HLA-DR 1.
Harris PE; Liu Z; Suciu-Foca N
J Immunol; 1992 Apr; 148(7):2169-74. PubMed ID: 1545124
[TBL] [Abstract][Full Text] [Related]
16. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Park SJ; Sadegh-Nasseri S; Wiley DC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11289-93. PubMed ID: 7479981
[TBL] [Abstract][Full Text] [Related]
17. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.
Newton-Nash DK; Eckels DD
J Immunol; 1993 Mar; 150(5):1813-21. PubMed ID: 7679697
[TBL] [Abstract][Full Text] [Related]
19. In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers.
Yang J; Jaramillo A; Shi R; Kwok WW; Mohanakumar T
Hum Immunol; 2004 Jul; 65(7):692-9. PubMed ID: 15301857
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
Li X; Li R; Li Z
Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
